Dr. Welslau on the Benefits of Biosimilars in DLBCL
Manfred Welslau, MD, discusses the potential benefits of using biosimilars in diffuse large B-cell lymphoma.
Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the potential benefits of using biosimilars in diffuse large B-cell lymphoma (DLBCL).
Due to lower market prices, biosimilars offer a more accessible options to patients in developed and underdeveloped countries, Welslau explains.
Notably, biosimilars have a different approval process compared with biologics, says Welslau. If the biosimilar agentdemonstrates clinical similarity to the reference biologic and does not demonstrate clinically meaningful differences regarding safety and efficacy, only 1 confirmatory phase 3 study is required to receive FDA and European Medicines Agency approval, Welslau concludes.
